Neuromyelitis optica spectrum disorder (NMOSD)-related disability was associated with quality of life (QoL) measures in patients with NMOSD, according to a study published in Multiple Sclerosis and Related Disorders.
“Disability accrual is a direct result of relapses in NMOSD; therefore, early intervention for relapse prevention is key to improving long-term QoL outcomes,” the authors of the study advised.
To analyze the association, they compared data from the Expanded Disability Status Scale (EDSS) and the EuroQol 5-dimensions (EQ-5D) of 2 clinical trials, the SAkuraSky (NCT02028884) and the SAkuraStar (NCT02073279).
Continue Reading
The authors observed a decrease in QoL at each incremental increase in the disability of each patient. The exception was the EDSS category 2.0-2.5, which presented with a marginally higher mean utility than the EDSS category 1.0-1.5. The association between EDSS and EQ-5D persisted between the treatment groups.
Read more about NMOSD patient education
In addition, the authors uncovered a potential use for EDSS in NMOSD.
“Although the EDSS has not yet been validated for use in NMOSD, the results of this analysis support its application in NMOSD, with further studies required,” they said.
SAkuraStar and SAkuraSky are randomized, placebo-controlled, parallel-assignment phase 3 studies designed to assess the efficacy and safety of satralizumab as monotherapy or add-on therapy, respectively, for treating patients with NMOSD.
References
Levy M, Haycox AR, Becker U, et al. Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: insights from the SAkura studies. Mult Scler Relat Disord. Published online October 15, 2021. doi:10.1016/j.msard.2021.103332
Efficacy and safety study of satralizumab (SA237) as add-on therapy to treat participants with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD). ClinicalTrials.gov. January 7, 2014. Updated September 16, 2021. Accessed November 18, 2021.
Efficacy and safety study of satralizumab (SA237) as monotherapy to treat participants with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD). ClinicalTrials.gov. February 27, 2014. Updated March 24, 2021. Accessed November 18, 2021.
